Freeline Therapeutics Holdings plc
General Information | |
Business: |
We are a clinical stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, including hemophilia B. We aim to deliver one-time gene therapy treatments that provide functional cures through permanently sustained physiological protein levels, leveraging the high expression enabled by our proprietary gene therapy platform. Our initial focus is on developing treatments for monogenic diseases with high unmet need. We are a fully integrated biotechnology company with internal expertise and capability across the value chain in gene therapy, including expression platform, research, manufacturing, clinical development and commercialization. Our pipeline includes two programs in the clinic and two late-stage preclinical product candidates, as well as research programs targeting novel applications for systemic gene therapy, for which we have, through owned and in-licensed intellectual property rights, development and worldwide commercial rights. |
Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Employees: | 208 |
Founded: | 2015 |
Contact Information | |
Address | Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX, United Kingdom |
Phone Number | +44 (0)1438 906870 |
Web Address | http://www.freeline.life |
View Prospectus: | Freeline Therapeutics Holdings plc |
Financial Information | |
Market Cap | $564.9mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-53.9 mil (last 12 months) |
IPO Profile | |
Symbol | FRLN |
Exchange | NASDAQ |
Shares (millions): | 8.8 |
Price range | $18.00 - $18.00 |
Est. $ Volume | $158.8 mil |
Manager / Joint Managers | J.P. Morgan/ Morgan Stanley/ Evercore |
CO-Managers | Wedbush Securities |
Expected To Trade: | 8/7/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |